Keyphrases
Previously Treated
100%
Single Technology Appraisal
100%
Sarilumab
100%
Evidence Review
100%
National Institutes of Health
100%
Rheumatoid Arthritis
100%
Methotrexate
84%
Tumour Necrosis Factor Inhibitor (TNFi)
69%
Conventional Disease-modifying Antirheumatic Drug
61%
Rituximab
53%
Quality-adjusted Life Years
46%
Life-years Gained
38%
Clinical Efficacy
30%
Incremental Cost-effectiveness Ratio
30%
Monotherapy
30%
Lack of Response
30%
Moderate Rheumatoid Arthritis
30%
Disease Activity Score 28 (DAS28)
30%
Cost-effectiveness
23%
Clinical Costs
15%
National Health Service
15%
Network Meta-analysis
15%
Placebo
7%
Years of Life Lost
7%
Appraisal Processes
7%
Health Personal
7%
Combination Therapy
7%
Inter-firm Networks
7%
Latent Class Approach
7%
Service Resources
7%
Effectiveness Review
7%
University of Sheffield
7%
Economic Evaluation
7%
Adalimumab
7%
Markov Model
7%
Cost Savings
7%
Technology-based
7%
Biologic Disease-modifying Antirheumatic Drugs
7%
Genzyme
7%
Moderate to Severe
7%
Personal Social Services
7%
Health Assessment Questionnaire Disability Index (HAQ-DI)
7%
28-joint Disease Activity Score
7%
Tocilizumab
7%
Randomized Controlled Trial
7%
Sanofi
7%
Research Technology
7%
Technology Assessment
7%
Nursing and Health Professions
Sarilumab
100%
Rheumatoid Arthritis
100%
Inflammatory Arthritis
100%
Methotrexate
78%
Tumor Necrosis Factor Inhibitor
64%
Disease Modifying Antirheumatic Drug
64%
Rituximab
50%
Quality Adjusted Life Year
42%
DAS28
35%
Monotherapy
28%
Incremental Cost-Effectiveness Ratio
28%
Clinical Effectiveness
28%
Cost Effectiveness Analysis
21%
Network Meta-Analysis
14%
Socialized Medicine
14%
Electroretinogram
7%
Health Assessment Questionnaire
7%
Tocilizumab
7%
Cost Control
7%
Adalimumab
7%
Biological Product
7%
Economic Evaluation
7%
Combination Therapy
7%
Placebo
7%
Medicine and Dentistry
Inflammatory Arthritis
100%
Rheumatoid Arthritis
100%
Sarilumab
100%
Methotrexate
78%
Disease Modifying Antirheumatic Drug
64%
TNF Inhibitor
64%
Rituximab
50%
Cost-Effectiveness Analysis
50%
Quality Adjusted Life Year
42%
DAS28
35%
Monotherapy
28%
Health Care Cost
14%
National Health Service
14%
Network Meta-Analysis
14%
Placebo
7%
Health Assessment Questionnaire
7%
Randomized Controlled Trial
7%
Combination Therapy
7%
Biological Product
7%
Tocilizumab
7%
Adalimumab
7%
Pharmacology, Toxicology and Pharmaceutical Science
Sarilumab
100%
Inflammatory Arthritis
100%
Rheumatoid Arthritis
100%
Methotrexate
78%
Disease Modifying Antirheumatic Drug
64%
Tumor Necrosis Factor Inhibitor
64%
Rituximab
50%
Monotherapy
28%
Randomized Controlled Trial
7%
Adalimumab
7%
Disease Activity Score
7%
Combination Therapy
7%
Biological Product
7%
Placebo
7%
Tocilizumab
7%
Arthropathy
7%